Sign up
Pharma Capital

Clinigen achieves a pharma first with EC Cardioxane approval

Shaun Chilton, chief executive of Clinigen Group PLC (LON:CLIN), tells Proactive the European Commission (EC) has approved an update to the product information for a key oncology product that would allow doctors to consider its use in children.

The label change relates to Cardioxane, which is given to protect the heart against certain chemotherapies called anthracyclines.

''With any claim you have to check out your facts but as far as we're able to tell no pharmaceutical company has ever overturned what was originally called an article 31 restriction placed on it'', Chilton says.

 

View full CLIN profile

Clinigen Group PLC Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.